DNA vaccines: application to tuberculosis.
Since the first observations in the early 1990s, the scientific literature on DNA vaccines has been growing exponentially. This article reviews the history and general principle, summarizes current knowledge on immune mechanisms, discusses safety considerations and highlights possible advantages of this technique as compared to the classic vaccines. Special emphasis is placed on the potential of DNA vaccines with respect to tuberculosis.
Huygen
K
K
Mycobacterial Immunology, Pasteur Institute, Brussels, Belgium. chuygen@ben.vub.ac.be
D000276:Adjuvants, Immunologic; D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology*; D001428:Bacterial Vaccines; D004269:DNA, Bacterial / Q000276:immunology*; D006360:Heat-Shock Proteins / Q000276:immunology; D006801:Humans; D008285:Major Histocompatibility Complex; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D010957:Plasmids; D014376:Tuberculosis / Q000276:immunology / Q000517:prevention & control*; D019444:Vaccines, DNA / Q000276:immunology / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D004269:DNA, Bacterial; D006360:Heat-Shock Proteins; D019444:Vaccines, DNA